Vanderbilt University Medical Center (VUMC)
R

Age Limits in Stem Cell Transplants and Cell Therapy

By Vanderbilt University Medical Center (VUMC) FEATURING Reena Jayani
By Vanderbilt University Medical Center (VUMC) FEATURING Reena Jayani
0 views
July 22, 2024
Comments 0
Login to view comments. Click here to Login

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi

Featured Video

01:29
Incyte

Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD

Recommended

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
16:57
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Lymphoma Highlights"

Feat. B. D. Cheson
22:37
Insights from 2023 ASH Annual Meeting

AML and MDS Highlights & Key Takeaways

Feat. T. Badar
13:07
Moffitt Cancer Center

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Feat. J. Chavez
17:51
Indy Hematology Review

Treatment of AML: Managing the Patient When Transplant Is Not an Opt…

Feat. H. Erba
31:53
Indy Hematology Review

HSCT in 2024: What Every Hematologist Needs to Know

Feat. R. Childs
27:47
Indy Hematology Review

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Feat. S. Smith
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
27:49
Insights from 2024 EHA Annual Meeting

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Feat. T. Badar
35:27
Louisville Hematology Highlights

Updates on Management of DLBCL

Feat. J. Leonard
10:04
Tara Graff

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

09:18
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Random…

Feat. J. Westin
19:10
5th SOHO Italy Annual Conference

SOHO Italy 2023: How I Treat AML at MD Anderson Cancer Center

Feat. H. Kantarjian
14:58
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Optimal Treatment Strategies for Younger P…

Feat. C. McMahon
22:30
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Emerging Treatment Options for AML in 2024

Feat. A. Perl
08:23
Total Health

R/R DLBCL Case Discussion: 81 y/o Male Needing 3rd Line Treatment

Feat. J. Chandler, B. Randolph, M. Onciu
48:04
Icahn School of Medicine at Mount Sinai

Integrating Targeted Therapies in AML

Feat. H. Kantarjian
22:11
SOHO Brazil 2024

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

Feat. A. Zelenetz
28:02
University of Colorado Division of Hematology

2024 Updates in AML

Feat. C. McMahon
20:34
UChicago Medicine

Sequencing of Bispecifics With Other Therapies in DLBCL

Feat. E. Budde
12:05
UChicago Medicine

The Evolving Role for Bispecific Antibodies in B-Cell Lymphoma

Feat. T. Mccabe
06:26
ecancer

Post-Transplant Cyclophosphamide Based GVHD Prophylaxis in Patients …

Feat. M. Al Malki, S. Devine
02:38
ecancer

EHA 2024 Insights: APOLLO Trial Summary - ATRA + ATO vs. Standard AT…

Feat. U. Platzbecker
02:01
Emanuele Angelucci

Administration and Dosing of Tagraxofusp for BPDCN

02:01
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Real-World Data From R/R BPDCN Treated With Tagra…

Feat. E. Angelucci
08:43
Nandita Khera

Maintaining QoL in Chronic GvHD

21:27
UChicago Medicine

Exploring the Value of PI3K in Lymphoma Treatment

Feat. C. Deng
23:51
Vanderbilt University Medical Center (VUMC)

Pre-Transplant Management of High-Risk AML

Feat. K. Fedorov
11:35
Vanderbilt University Medical Center (VUMC)

Prevention and Management of Post-SCT Relapse in Acute Leukemias

Feat. A. Jallouk
17:42
Vanderbilt University Medical Center (VUMC)

Managing Relapse After CAR-T Therapy in Lymphoma: Strategies and Con…

Feat. B. Dholaria
27:49
Insights from 2024 EHA Annual Meeting

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Feat. T. Badar
27:26
SOHO Brazil 2024

Where I Use Azacitidine and Venetoclax in AML: Present and Future

Feat. J. Lancet
19:21
SOHO Brazil 2024

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

Feat. J. Lancet
20:25
SOHO Brazil 2024

What Is the Best Timing for Bispecific Antibodies and CAR-T Therapy …

Feat. A. Zelenetz
14:17
SOHO Brazil 2024

DLBCL Pts Ineligible for CAR-T Therapy: Do They Exist and How Do We …

Feat. A. Zelenetz
15:02
SOHO Brazil 2024

Summary of Updates in R/R DLBCL Treatment

Feat. A. Alencar
22:11
SOHO Brazil 2024

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

Feat. A. Zelenetz
20:33
SOHO Brazil 2024

The Gold Standard in the Use of FLT3 and IDH Inhibitors in AML

Feat. J. Lancet
13:58
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Intrathecal Rituximab + Dex for Refractory Sanctu…

Feat. M. Salamoon